Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2021

03.01.2021 | Breast Oncology

Outcomes with Partial Breast Irradiation vs. Whole Breast Irradiation: a Meta-Analysis

verfasst von: Chirag Shah, MD, Xuefei Jia, Brian P. Hobbs, PhD, Rahul D. Tendulkar, MD, Sarah M. C. Sittenfeld, MD, Zahraa Al-Hilli, MD, Douglas W. Arthur, MD, Martin E. Keisch, MD, Atif J. Khan, MD, Simona F. Shaitelman, MD, EDM, John Boyages, MD, David Wazer, MD, Neilendu Kundu, MD, Frank A. Vicini, MD, FACR

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Several randomized trials have been performed comparing partial breast irradiation (PBI) and whole breast irradiation (WBI) though controversy remains, including regarding differences by PBI technique. We performed a meta-analysis to compare results between WBI versus PBI and between PBI techniques.

Methods

A systematic review was performed to identify modern randomized studies listed in MEDLINE from 2005 to 2020. PBI trials were divided into external beam radiation and brachytherapy techniques, with intraoperative radiation excluded. A Bayesian logistic regression model evaluated the risk of ipsilateral breast tumor recurrence (IBTR) and acute and chronic toxicities. The primary outcome was IBTR at 5 years with WBI compared with PBI.

Results

A total of 9758 patients from 7 studies were included (4840-WBI, 4918-PBI). At 5 years, no statistically significant difference in the rate of IBTR was noted between PBI (1.8%, 95% HPD 0.68–3.2%) and WBI (1.7%, 95% HPD 0.92–2.4%). By PBI technique, the 5-year rate of IBTR rate for external beam was 1.7% and 2.2% for brachytherapy. Rates of grade 2 + acute toxicity were 7.1% with PBI versus 47.5% with WBI. For late toxicities, grade 2/3 rates were 0%/0% with PBI compared with 1.0%/0% with WBI.

Conclusions

IBTR rates were similar between PBI and WBI with no significant differences noted by PBI technique; PBI had reduced acute toxicities compared to WBI. Because studies did not provide toxicity data in a consistent fashion, definitive conclusions cannot be made with additional data from randomized trials needed to compare toxicity profiles between PBI techniques.
Literatur
1.
Zurück zum Zitat Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.CrossRef Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.CrossRef
2.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data on 10,801 women in 17 randomised trials. Lancet. 2011;378:1707-16.CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data on 10,801 women in 17 randomised trials. Lancet. 2011;378:1707-16.CrossRef
3.
Zurück zum Zitat Hasan Y, Waller J, Yao K, Chmura SJ, Huo D. Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States. Breast Cancer Res Treat. 2017;162:317–28.CrossRef Hasan Y, Waller J, Yao K, Chmura SJ, Huo D. Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States. Breast Cancer Res Treat. 2017;162:317–28.CrossRef
4.
Zurück zum Zitat Correa C, Hariss EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;17:73–9.CrossRef Correa C, Hariss EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;17:73–9.CrossRef
5.
Zurück zum Zitat Shah C, Vicini F, Shaitelman SF, et al. The American Brachytherapy Society consensus statement for accelerated partial breast irradiation. Brachytherapy. 2018;17:154–70.CrossRef Shah C, Vicini F, Shaitelman SF, et al. The American Brachytherapy Society consensus statement for accelerated partial breast irradiation. Brachytherapy. 2018;17:154–70.CrossRef
6.
Zurück zum Zitat Liberati A, Altman DG, Tatzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRef Liberati A, Altman DG, Tatzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRef
7.
Zurück zum Zitat Polgar C, Fodor J, Major T, et al. Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiother Oncol. 2013;108:197–202.CrossRef Polgar C, Fodor J, Major T, et al. Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiother Oncol. 2013;108:197–202.CrossRef
8.
Zurück zum Zitat Polgar C, Fodor J, Major T, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma- 5-year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:694–702.CrossRef Polgar C, Fodor J, Major T, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma- 5-year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:694–702.CrossRef
9.
Zurück zum Zitat Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2016;387:229–38. Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2016;387:229–38.
10.
Zurück zum Zitat Polgar C, Ott OJ, Hildebrandt G, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:259–68.CrossRef Polgar C, Ott OJ, Hildebrandt G, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:259–68.CrossRef
11.
Zurück zum Zitat Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019;394:2155–64.CrossRef Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019;394:2155–64.CrossRef
12.
Zurück zum Zitat Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): aa randomised controlled trial. Lancet. 2019;394:2165–72. Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): aa randomised controlled trial. Lancet. 2019;394:2165–72.
13.
Zurück zum Zitat Olivotto I, Whelan TJ, Parpia S, et al. Interim cosmetic and toxicity results from RAPID: A randomized trial of accelerated partial breast irradiation using 3D conformal external beam radiation therapy. J Clin Oncol. 2013;31:4038–45.CrossRef Olivotto I, Whelan TJ, Parpia S, et al. Interim cosmetic and toxicity results from RAPID: A randomized trial of accelerated partial breast irradiation using 3D conformal external beam radiation therapy. J Clin Oncol. 2013;31:4038–45.CrossRef
14.
Zurück zum Zitat Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;51:451–63.CrossRef Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;51:451–63.CrossRef
15.
Zurück zum Zitat Meattini I, Saieva C, Lucidi S, et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Res. 80:GS4–06. Meattini I, Saieva C, Lucidi S, et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Res. 80:GS4–06.
16.
Zurück zum Zitat Coles C, Agarwal R, Ah-See ML, et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). Eur J Cancer. 2016;57:S4. Coles C, Agarwal R, Ah-See ML, et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). Eur J Cancer. 2016;57:S4.
17.
Zurück zum Zitat Rodriguez N, Sanz X, Dengra J, et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2013;87:1051–7.CrossRef Rodriguez N, Sanz X, Dengra J, et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2013;87:1051–7.CrossRef
18.
Zurück zum Zitat Marta GN, Macedo CR, Carvalho Hde A, et al. Accelerated partial breast irradiation for breast cancer: systematic review and meta-analysis of 8653 women in eight randomized trials. Radiother Oncol. 2015;114:42–9.CrossRef Marta GN, Macedo CR, Carvalho Hde A, et al. Accelerated partial breast irradiation for breast cancer: systematic review and meta-analysis of 8653 women in eight randomized trials. Radiother Oncol. 2015;114:42–9.CrossRef
19.
Zurück zum Zitat Hickey BE, Lehman M, Francis DP, et al Partial breast irradiation for early breast cancer. Cohrance Database Syst Rev. 2016;7:CD007077. Hickey BE, Lehman M, Francis DP, et al Partial breast irradiation for early breast cancer. Cohrance Database Syst Rev. 2016;7:CD007077.
20.
Zurück zum Zitat Korzets Y, Fyles A, Shepshelovich D, et al. Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019;175:531–45.CrossRef Korzets Y, Fyles A, Shepshelovich D, et al. Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019;175:531–45.CrossRef
21.
Zurück zum Zitat Vaidya JS, Bulsara M, Wenz F, et al. Reduced mortality with partial-breast irradiation for early breast cancer: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys. 2016;96:259–65.CrossRef Vaidya JS, Bulsara M, Wenz F, et al. Reduced mortality with partial-breast irradiation for early breast cancer: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys. 2016;96:259–65.CrossRef
22.
Zurück zum Zitat Shah C, Wobb J, Khan A. Intraoperative radiation therapy in breast cancer: still not ready for prime time. Ann Surg Oncol. 2016;23:1796–8.CrossRef Shah C, Wobb J, Khan A. Intraoperative radiation therapy in breast cancer: still not ready for prime time. Ann Surg Oncol. 2016;23:1796–8.CrossRef
23.
Zurück zum Zitat White JR, Winter K, Cecchini RS, et al. Cosmetic outcome from post-lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG0413 Phase III Clinical Trial. Int J Radiat Oncol Biol Phys. 2019;105:S5. White JR, Winter K, Cecchini RS, et al. Cosmetic outcome from post-lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG0413 Phase III Clinical Trial. Int J Radiat Oncol Biol Phys. 2019;105:S5.
Metadaten
Titel
Outcomes with Partial Breast Irradiation vs. Whole Breast Irradiation: a Meta-Analysis
verfasst von
Chirag Shah, MD
Xuefei Jia
Brian P. Hobbs, PhD
Rahul D. Tendulkar, MD
Sarah M. C. Sittenfeld, MD
Zahraa Al-Hilli, MD
Douglas W. Arthur, MD
Martin E. Keisch, MD
Atif J. Khan, MD
Simona F. Shaitelman, MD, EDM
John Boyages, MD
David Wazer, MD
Neilendu Kundu, MD
Frank A. Vicini, MD, FACR
Publikationsdatum
03.01.2021
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2021
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-09447-w

Weitere Artikel der Ausgabe 9/2021

Annals of Surgical Oncology 9/2021 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.